BridgeBio's heart disease drug meets late-stage study goal
BRIDGEBIO Pharma’s experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares up 60 per cent in premarket trading on Monday (Jul 17).
The drug was 1.8 times better than placebo when measured for preventing death, hospitalisation and improvement in six minutes’ walking distance as part of the main goal, the company said.
The drug, acoramidis, also helped improve survival by 81 per cent in patients on the treatment compared to 74 per cent on the placebo, and also reduced frequency of heart disease-related hospitalisation by 50 per cent.
No safety concerns were identified, the company said.
BridgeBio plans to submit the data to the US Food and Drug Administration (FDA) by the end of 2023, as part of its marketing application. The company also expects to file in additional markets next year.
Acoramidis is being developed to treat transthyretin amyloid cardiomyopathy, which is characterised by the build-up of abnormal deposits of protein called amyloid, that can lead to heart failure.
Alnylam Pharmaceuticals is also seeking approval for its drug, patisiran, for the same condition, and the FDA is set to decide by Oct 8.
Alnylam’s drug is already approved to treat polyneuropathy, another symptom of the disease, which causes malfunction of nerves that results in tingling, numbness and kidney dysfunction.
Other drugs that treat symptoms of the disease include Pfizer’s tafamidis, sold under the brand names Vyndaqel and Vyndamax, for polyneuropathy and cardiomyopathy, respectively. Ionis Pharmaceuticals’ injection, Tegsedi, targets polyneuropathy. REUTERS
Share with us your feedback on BT's products and services
